This research study is currently not recruiting patients.

A Phase 2b Multicenter Double-blind Randomized Study to Investigate the Efficacy and Safety of Different Combinations Regimens Including JNJ-73763989 and JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Brief description of study

The purpose of this study is to see if the combination of study drugs, JNJ-73763989 and/or JNJ- 56136379, with a nucleoside/nucleotide analogue also referred to as NA, is safe and useful for treating patients with chronic Hepatitis B virus (HBV) infection. NA, which may either be entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF), are Food and Drug Administration (FDA) approved drugs given to treat chronic HBV. The study drugs and their use with NA are considered investigational because the drugs and combination of drugs are being tested in research studies like this one and are not FDA-approved for routine clinical use. These drugs work by helping to prevent the multiplication of the Hepatitis B virus.


Clinical Study Identifier: s19-00294
ClinicalTrials.gov Identifier: NCT03982186